Bioactivity:

CHMFL-ABL-039 is a type II native ABL kinase and drug-resistant V299L mutant BCR-ABL inhibitor (IC50s: 7.9 nM and 27.9 nM) used in the research of chronic myeloid leukemia.

CAS nr:

2304344-56-5

Purity:

98%

Molecular Weight:

594,63

SMILES:

O=C(NC1=CN=C(NC(C2CC2)=O)C=C1)CC3=CC=C(NC(C4=CC=C(CN5CCN(C)CC5)C(C(F)(F)F)=C4)=O)C=C3

Formula:

C31H33F3N6O3

Pathway:

Angiogenesis,Tyrosine Kinase/Adaptors,Cytoskeletal Signaling

Target:

Bcr-Abl,Bcr-Abl,Bcr-Abl